Infants born to narcotic dependent mothers: physical growth patterns in the first 12 months of life

J C Vance1, D C Chant, D I Tudehope

  • 1Department of Paediatrics and Child Health, Mater Children's Hospital, South Brisbane, Australia.

Insights

Infants born to narcotic-dependent mothers show intrauterine growth retardation at birth. By 12 months, their growth catches up, but may still be influenced by maternal drug use during pregnancy.

Area of Science:

  • Neonatal development
  • Pediatric growth studies
  • Maternal substance use impact

Background:

  • Infants born to narcotic-dependent mothers (INDM) face unique developmental challenges.
  • Understanding their physical growth is crucial for early intervention.

Purpose of the Study:

  • To track the physical growth of INDM over their first year.
  • To investigate the correlation between maternal drug use patterns and infant growth.

Main Methods:

  • A cohort of 43 INDM was monitored for 12 months.
  • Weight and length were measured and converted to Z scores.
  • Maternal drug use, demographics, and neonatal withdrawal were assessed via questionnaires.

Main Results:

  • 55.8% of INDM experienced neonatal drug withdrawal requiring treatment.
  • Infants exhibited intrauterine growth retardation at birth (low Z scores).
  • Catch-up growth occurred by 12 months, though Z scores remained below zero; higher maternal methadone dosage correlated with persistent weight retardation.

Conclusions:

  • INDM show initial intrauterine growth retardation, with growth approaching community norms by 12 months.
  • Maternal narcotic use during pregnancy appears to influence infant growth patterns.
  • Further research can clarify the long-term effects and optimal support strategies.
Abstract

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...